Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22810865 | 0.84 | HMGCR (0.31) | — | |
| SCHEMBL14417165 | 0.83 | AR (0.42) | CA12CA9ACHE | |
| SCHEMBL20997233 | 0.83 | — | — | |
| SCHEMBL15059775 | 0.83 | — | — | |
| SCHEMBL20215059 | 0.83 | GABRA2 (0.35) | GABRA2GABRB2DPP4HRH4HRH3 | |
| SCHEMBL25009052 | 0.83 | ACHE (0.35) | GABRA2GABRB2ACHE | |
| SCHEMBL22021705 | 0.83 | — | — | |
| SCHEMBL27249327 | 0.83 | HTT (0.31) | — | |
| SCHEMBL18367586 | 0.81 | GABRA2 (0.39) | GABRA2GABRB2DPP4HRH4HRH3 | |
| SCHEMBL22077974 | 0.81 | ACHE (0.36) | GABRA2GABRB2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12018315-B2 | Peptide nucleic acid functionalized hydrogel microneedles for sampling and detection of interstitial fluid nucleic acids | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | ALPHA-9 ONCOLOGY INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| WO-2023217851-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF-κB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
| US-20230349907-A1 | BIOPROBES FOR LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2023-11-02 | — | — | US | disclosed |
| US-20230271994-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | UNIV YALE (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230270876-A1 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | NOVARTIS AG (CH) | 2023-08-31 | — | — | US | disclosed |
| US-11739325-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-29 | — | — | US | disclosed |
| US-7928122-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100234435-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | BHATTACHARYA SAMIT K | 2010-09-16 | — | — | US | disclosed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| US-7790743-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| US-7745460-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | BAUSCH + LOMB IRELAND LIMITED (IE) | 2010-04-15 | — | — | US | disclosed |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271994-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, MSR1, LDLR | GABRA2 1442/4885GABRB2 1315/4885DPP4 1227/4885 |
| US-20080176896-A1 | Modulators of cellular adhesion | ITGB1, VCAM1, ITGB8 | GABRA2 704/4885GABRB2 638/4885DPP4 4224/4885 |
| US-20100234435-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | CCNI, CCNA1, PCNA | GABRA2 2844/4885GABRB2 3297/4885DPP4 2394/4885 |
| US-20230270876-A1 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | PTMS, FCGR2A, FCGR3B | GABRA2 393/4885GABRB2 1191/4885DPP4 3193/4885 |
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | KLK3, FOLH1, TMEM14C | GABRA2 1471/4885GABRB2 1542/4885DPP4 1898/4885 |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | GABRA2 723/4885GABRB2 652/4885DPP4 4202/4885 |
| US-20230349907-A1 | BIOPROBES FOR LYSYL OXIDASES AND USES THEREOF | MAOB, LOX, LPO | GABRA2 1959/4885GABRB2 1778/4885DPP4 2548/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | GABRA2 2246/4885GABRB2 1724/4885DPP4 3330/4885 |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | GABRA2 565/4885GABRB2 978/4885DPP4 2410/4885 |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | GABRA2 685/4885GABRB2 643/4885DPP4 4221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.